Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frederick L Locke

Showing results (41-50 of 234) with videos related to

Pageof 24
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 7, 2025
Facts and hopes: CAR-T cell therapy and Immune contexture in Non-Hodgkin LymphomaAssia Hijazi, Frederick L Locke, Nathalie Scholler, et al.
Journal of Medical Economics|March 11, 2021
Cost effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the United StatesRongzhe Liu, Olalekan O Oluwole, Ibrahim Diakite, et al.
Leukemia & Lymphoma|November 23, 2022
Psychosocial characteristics of patients undergoing cellular immunotherapies and their caregivers across timeKedar Kirtane, Maija Reblin, Laura B Oswald, et al.
Blood Advances|May 26, 2023
CAR T-cell therapy has comparable efficacy with autologous transplantation in older adults with DLBCL in partial responseOthman S Akhtar, Biwei Cao, Xuefeng Wang, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 20, 2020
Response to Letter to Editor Regarding "Comparing Efficacy, Safety, and Preinfusion Period of Axicabtagene Ciloleucel versus Tisagenlecleucel in Relapsed/Refractory Large B Cell Lymphoma"Olalekan O Oluwole, Jeroen P Jansen, Vincent W Lin, et al.
Blood Advances|June 11, 2024
CAR T-cell toxicities: from bedside to bench, how novel toxicities inform laboratory investigationsFabiana Perna, Samir Parekh, Caroline Diorio, et al.
Journal of Medical Economics|January 19, 2024
Cost-effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for the treatment of 3L + relapsed/refractory large B-cell lymphoma in the United States: incorporating longer survival resultsOlalekan O Oluwole, Markqayne D Ray, Neil Davies, et al.
Blood Advances|November 7, 2025
Racial and Clinical Determinants of Response in 2,304 r/r BCL Treated with Anti-CD19 CAR T-Cells in Clinical TrialsSoon Jye Kho, Sheila S Diamond, Penelope Lafeuille, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 21, 2020
Comparing Efficacy, Safety, and Preinfusion Period of Axicabtagene Ciloleucel versus Tisagenlecleucel in Relapsed/Refractory Large B Cell LymphomaOlalekan O Oluwole, Jeroen P Jansen, Vincent W Lin, et al.
Hematological Oncology|May 10, 2025
Efficacy of Axicabtagene Ciloleucel Compared to Historical Treatments for Relapsed/Refractory Diffuse Large B-Cell Lymphoma of Asian Descent: A Matching Adjusted Indirect Comparison of ZUMA-1 vs REAL-TRENDFrederick L Locke, Graeme Ball, Markqayne D Ray, et al.
Pageof 24

Showing results (41-50 of 234) with videos related to

Sort By:
Pageof 24
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 7, 2025
Facts and hopes: CAR-T cell therapy and Immune contexture in Non-Hodgkin LymphomaAssia Hijazi, Frederick L Locke, Nathalie Scholler, et al.
Journal of Medical Economics|March 11, 2021
Cost effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the United StatesRongzhe Liu, Olalekan O Oluwole, Ibrahim Diakite, et al.
Leukemia & Lymphoma|November 23, 2022
Psychosocial characteristics of patients undergoing cellular immunotherapies and their caregivers across timeKedar Kirtane, Maija Reblin, Laura B Oswald, et al.
Blood Advances|May 26, 2023
CAR T-cell therapy has comparable efficacy with autologous transplantation in older adults with DLBCL in partial responseOthman S Akhtar, Biwei Cao, Xuefeng Wang, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 20, 2020
Response to Letter to Editor Regarding "Comparing Efficacy, Safety, and Preinfusion Period of Axicabtagene Ciloleucel versus Tisagenlecleucel in Relapsed/Refractory Large B Cell Lymphoma"Olalekan O Oluwole, Jeroen P Jansen, Vincent W Lin, et al.
Blood Advances|June 11, 2024
CAR T-cell toxicities: from bedside to bench, how novel toxicities inform laboratory investigationsFabiana Perna, Samir Parekh, Caroline Diorio, et al.
Journal of Medical Economics|January 19, 2024
Cost-effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for the treatment of 3L + relapsed/refractory large B-cell lymphoma in the United States: incorporating longer survival resultsOlalekan O Oluwole, Markqayne D Ray, Neil Davies, et al.
Blood Advances|November 7, 2025
Racial and Clinical Determinants of Response in 2,304 r/r BCL Treated with Anti-CD19 CAR T-Cells in Clinical TrialsSoon Jye Kho, Sheila S Diamond, Penelope Lafeuille, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 21, 2020
Comparing Efficacy, Safety, and Preinfusion Period of Axicabtagene Ciloleucel versus Tisagenlecleucel in Relapsed/Refractory Large B Cell LymphomaOlalekan O Oluwole, Jeroen P Jansen, Vincent W Lin, et al.
Hematological Oncology|May 10, 2025
Efficacy of Axicabtagene Ciloleucel Compared to Historical Treatments for Relapsed/Refractory Diffuse Large B-Cell Lymphoma of Asian Descent: A Matching Adjusted Indirect Comparison of ZUMA-1 vs REAL-TRENDFrederick L Locke, Graeme Ball, Markqayne D Ray, et al.
Pageof 24